Complete Inhibition of Endotoxin-Induced Coagulation Activation in Chimpanzees with a Monoclonal Fab Fragment against Factor VII/VIIa

Summary

Gram-negative sepsis is oftentimes complicated by activation of coagulation with disseminated intravascular coagulation and microthrombosis. This may contribute to the associated morbidity, multiple organ failure and death. Recent studies have established that the tissue factor-dependent pathway of blood coagulation has a significant participatory role in the initial endotoxin-induced activation of coagulation. Tissue factor (TF), expressed on the surface of activated monocytes and endothelial cells forms cell surface complexes with free circulating factors VII and VIIa. The latter complex proteolytically activates factors X and IX. Recent in vivo experiments have shown that a rapidly neutralizing TF monoclonal antibody prevents and arrests the endotoxin- induced activation of coagulation and similar studies have shown to reduce mortality in baboons. In this study we describe the preparation of a factor VII/VIIa neutralizing monoclonal Fab fragment and characterize its effect on in vivo activation of coagulation during experimental endotoxemia in chimpanzees.

Four chimpanzees received a bolus intravenous injection of 4 ng/kg endotoxin in combination with Fab fragments of a factor VII/VIIa neutralizing murine monoclonal antibody (12D10) at a dose of either 50 μg/kg (n = 2) or 100 μfig/kg (n = 2). Four control animals received a bolus injection of endotoxin alone. Administration of the 12D10 Fab fragments, immediately preceding the endotoxin bolus injection, effectively blocked the endotoxin-induced activation of coagulation. Plasma levels of products of in vivo activation, namely F1+2, TAT complexes and FpA remained at baseline values. The administration of 12D10 resulted in a rapid decline in factor VII/VIIa antigen levels which remained below 5 ng/ml for 180-240 min, followed by a rapid return to baseline levels. Endotoxin administration resulted in activation of the fibrinolytic system as reflected by a rapid increase in plasma plasmin- α²-antiplasmin complexes. Administration of 12D10 was without effect on the endotoxin-induced fibrinolytic activation.

In conclusion, this study confirmed the importance of the TF: VII complex in the initial, endotoxin-induced activation of coagulation which was completely blocked by neutralizing all free and tissue factor-complexed factor VII/VIIa by a specific monoclonal Fab fragment. Activation of fibrinolysis was not influenced. Therefore, neutralization of factor VII/VIIa might be a promising therapeutic option in preventing endotoxin-induced microthrombosis during Gram-negative sepsis.

• References

• 1 Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombo- hemorragic disorders. In: Hemostasis and Thrombosis: basic principles and clinical practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds J.B.Lippincott; Philadelphia: PA 1987. pp 975-1015
• 2 Østerud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to unfavourable prognosis. Thromb Haemost 1983; 49: 5-7
• 3 Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992; 34 (Suppl) S13-S25
• 4 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-623
• 5 Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stem D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 1992; 80: 966-974
• 6 Broze GJ. Binding of human factor VII and Vila to monocytes. J Clin Invest 1982; 70: 526-535
• 7 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis Am J Pathol 1989; 134: 1087-1097
• 8 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localisation of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl AcadSci 1989; 86: 2839-2843
• 9 Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation factor. Thromb Res 1985; 40: 351-358
• 10 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537
• 11 Nawroth PP, Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
• 12 Rao LV M, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-6691
• 13 Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158-2166
• 14 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 15 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor Vila: Effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425
• 16 Lawson JH, Mann KG. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 1991; 266: 11317-11327
• 17 Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw LB, Catlett R, Blick K, Edgington TS, Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1990; 33: 127-137
• 18 Levi M, ten CateH, Van der Poll T, Van Deventer SJ H. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
• 19 Fair DS. Quantitation of factor VII in the plasma of normal and warfarin treated individuals by radioimmunoassay. Blood 1983; 62: 784-791
• 20 Soule HR, Linder E, Edgington TS. Membrane 126-kilodalton phosphogly- coprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells. Proc Natl Acad Sci USA 1983; 80: 1332-1336
• 21 Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
• 22 Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated humanmonocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-395
• 23 Pixley RA, De LaCadena, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB, Colman RW. The contact systems contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 1993; 91: 61-68
• 24 Warr TA, Rao LV M, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of antitissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489
• 25 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor IX and factor X by recombinant factor Vila in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
• 26 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII- tissue factor complex and also inhibits factor Xa: Insight into its possible mechanisms of action. Blood 1988; 71: 335-343
• 27 Levi M, ten Cate H, Bauer KA, Van der Poll T, Edgington TS, Biiller HR, van Deventer SJ H, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
• 28 Van derPoll, Levi M, Van Deventer SJ H, ten CateH, Haagmens BL, Biemond BJ, Biiller HR, Hack CE, ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451
• 29 Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ H, Eeren-berg AJ M, de Groot ER, Jansen J, Gallati H, Biiller HR, ten Cate JW, Aar- den LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
• 30 Creasey AA, Chang AC K, Feigen L, Wiin TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860
• 31 Taylor Jr FB, Chang AC K, Peer GT, Mather K, Blick R, Catlett R, Lockhart MS, Esmon CT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-368
• 32 Taylor Jr FB, Chang AC K, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusions in the baboon. J Clin Invest 1987; 79: 918-925